| Autor: |
Patel Harsh, Li Jiaxin, Bo Letao, Mehta Riddhi, Ashby Charles R., Wang Shanzhi, Cai Wei, Chen Zhe-Sheng |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Medical Review, Vol 4, Iss 1, Pp 5-30 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2749-9642 |
| DOI: |
10.1515/mr-2023-0058 |
| Popis: |
Cancer nanomedicine is defined as the application of nanotechnology and nanomaterials for the formulation of cancer therapeutics that can overcome the impediments and restrictions of traditional chemotherapeutics. Multidrug resistance (MDR) in cancer cells can be defined as a decrease or abrogation in the efficacy of anticancer drugs that have different molecular structures and mechanisms of action and is one of the primary causes of therapeutic failure. There have been successes in the development of cancer nanomedicine to overcome MDR; however, relatively few of these formulations have been approved by the United States Food and Drug Administration for the treatment of cancer. This is primarily due to the paucity of knowledge about nanotechnology and the fundamental biology of cancer cells. Here, we discuss the advances, types of nanomedicines, and the challenges regarding the translation of in vitro to in vivo results and their relevance to effective therapies. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
